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Highlights  1 
x The graft versus host disease free, relapse free survival is 34% after transplantation in 2 
lymphomas;  3 
x Reduced extensive chronic GVHD with a combination of ATG and Rituximab in recipients of 4 
unrelated graft 5 
x One Rituximab Infusion  prevents EBV-related lymphoproliferative disorders  6 
Abstract 7 
The treatment of patients with refractory/relapsed B-Cell non-Hodgkin lymphoma (NHL) is evolving due to the 8 
availability of novel drugs. Allogeneic stem cell transplantation (alloSCT) can be curative, but its morbidity and 9 
mortality remain a matter of concern. We conducted a multicentre prospective phase II trial to evaluate the benefit of 10 
including only one dose of Rituximab (R) in the conditioning regimen before alloSCT. The primary end-point was 11 
progression-free survival. The study enrolled 121 patients with relapsed/refractory B-cell lymphomas. The conditioning 12 
regimen consisted of thiotepa, cyclophosphamide, fludarabine and R (500 mg/ms). Rabbit anti-thymocyte globulin 13 
(ATG) was administered only in case of  unrelated donors. Sixty-seven (55%) and fifty-four (45%) patients received 14 
grafts from related and unrelated donors, respectively. The crude cumulative incidence (CCI) of non-relapse mortality 15 
(NRM) was 21% at 3-years. The CCI of chronic GVHD at 3-years was 54% and 31% in recipients of matched sibling 16 
and unrelated grafts, respectively. At a median follow-up of 41 months, the estimated 3-years progression-free and 17 
overall survival were 50% and 61%, respectively. Long-term outcome was also evaluated with the composite end-point 18 
of graft-versus-host disease-free and relapse-free survival (GRFS). This is the first work evaluating the GRFS in a 19 
prospective trial of lymphomas patients: the 1 and 3-years GRFS were 40% and 34%, respectively. AlloSCT can cure a 20 
fraction of patients with rather low NRM and an encouraging PFS and GRFS. 21 
 22 
Keywords: Rituximab,lymphomas, graft-versus-host disease-free/relapse-free survival 23 
24 




Rituximab-based chemoimmunotherapy has improved the survival rate of patients with indolent and aggressive B-cell 26 
non-Hodgkin lymphoma (NHL) (1,2), but 50% of them fail to respond or relapse and only a fraction could be cured by 27 
autologous stem cell transplantation (autoSCT). Despite an increase of novel drugs and treatments (3), allogeneic stem 28 
cell transplantation (alloSCT) still represents the only chance of cure for patients relapsing after autoSCT or two lines of 29 
chemo-immunotherapy. In previous studies with reduced-intensity conditioning, we already reported a 5-year 30 
progression-free survival (PFS) of 57% and 54% in indolent and aggressive lymphomas, respectively (4,5). 31 
Severe acute graft-versus-host disease (GVHD) and extensive chronic GVHD (6,7) are the two main complications 32 
associated to transplantation and may affect both non-relapse mortality (NRM) and quality of life. In the last years, a 33 
better understanding of GVHD biology prompted the design of novel GVHD prophylaxis regimens including the use of 34 
post-transplant cyclophosphamide or proteasome inhibitors, but the gold standard is still based on calcineurin inhibitors 35 
and methotrexate or mycophenolate mofetil (8-12).  36 
B cells have a role in the pathogenesis of both acute GVHD (for their role as antigen-presenting cells) and chronic 37 
GVHD (for the production of autoantibodies from autoreactive B cells) (13).  Rituximab (R) has been introduced during 38 
conditioning regimen in very few trials, however the results on disease control and  prevention of acute or chronic 39 
GVHD are still unclear (14-16). The major experience derived from the pivotal studies of Khouri (14)  that showed a 40 
rather good disease control with the unexpected finding of a limited incidence of acute and chronic extensive GVHD. 41 
In the present multicenter prospective phase II study, we investigated the effect of a single dose of R (500mg/ms) in 42 
combination with a reduced-intensity conditioning (RIC) regimen on the progression-free survival of 43 
refractory/relapsed B-cell lymphomas.  In addition also overall survival, incidence of acute and chronic GVHD, and the 44 
GVHD-free, relapse-free survival (GRFS) were evaluated.  45 
 46 
 47 
Materials and Methods 48 
Patient characteristics 49 
Between December 2007 and December 2015, 121 patients were enrolled in a prospective study (EUDRACT 2007- 50 
003657- 87) involving 22 Italian Hematology Divisions. Inclusion criteria were as follows: i) patients were diagnosed 51 
with CD20+ B-cell NHL [i.e. Chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), follicular 52 
lymphoma (FL), mantle cell lymphoma (MCL), de novo or transformed diffuse large B-cell lymphoma (DLBCL)]  53 
relapsing or refractory after at least two lines of treatment or after failure of autoSCT; ii) MCL and DLBCL were 54 
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required to have chemosensitive disease; chemorefractory disease was allowed only for indolent lymphomas. Exclusion 55 
criteria were central nervous system localization, positive serologic markers for human immunodeficiency virus (HIV), 56 
active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, ejection fraction < 45% (or myocardial stroke in 57 
the last year), DLCO < 50%, no adequate renal and hepatic functions (clearance of creatinine < 50 ml/min, serum 58 
bilirubin levels > 2 the upper normal limit). All the patients received R-chemo as salvage before the transplant phase. 59 
The study was approved by the Institutional Review Board of all participating centers. 60 
 61 
Donors and treatment plan 62 
Donors age ranged between 18 and 65 years old in the case of identical sibling donors and 18 and 60 years old in the 63 
case of unrelated donors, The availability of human leukocyte antigen (HLA)-identical or one antigen mismatched 64 
(class I) sibling donors, or unrelated donors mismatched by one antigen or allele at HLA-A, HLA-B, HLA-C, HLA-65 
DRB1, HLA-DQB1 loci, as identified by high or intermediate resolution typing. 66 
Patients were registered at time of relapse. At registration patients were treated with salvage R-chemotherapy. The 67 
choice of the salvage regimen was left to center preference. All the patients included in this prospective trial received 68 
the following drugs intravenous: rituximab (500 mg/ms; day –6), thiotepa (6 mg/kg every 12 hours for 2 doses; day –5), 69 
cyclophosphamide (30 mg/kg; days –4 and –3) and fludarabine (30 mg/ms; days –4 and –3), which was administered 4 70 
hours post-cyclophosphamide administration. The choice to administer only one dose of R was related to the fact that 71 
Rituximab was already administered with the previous salvage chemo-immunotherapy. In the case of matched related 72 
sibling donors, the GVHD prophylaxis consisted of intravenous or oral cyclosporine A, adjusted to maintain blood 73 
levels at 200–300 ng/ml, and a short course of intravenous methotrexate (10 mg/ms on day +1, and 8 mg/ms on days +3 74 
and +6). Patients with a class I antigen mismatch (sibling donors) or with unrelated donors received intravenous rabbit 75 
anti-thymocyte globulin (Thymoglobuline, Genzyme-Sanofi; 0.5 mg/kg on day –4, 3 mg/kg on day –3, 3.5 mg/kg on 76 
day –2). On day 0 patients received stem cells > 3 x108/kg total nucleated stem cells in case of bone marrow and 77 
≥4x106/kg CD34+ in case of peripheral blood stem cells. In absence of active acute GVHD, GVHD prophylaxis was 78 
administered until day 100 for siblings and day 150 for unrelated donors (details on immunesuppression tapering are 79 
given in Supplemental Material). Recommendations for supportive care were previously described (5). 80 
Study endpoints 81 
The primary endpoint of the study was progression-free survival (PFS). The secondary endpoints were non-relapse 82 
mortality (NRM), acute GVHD incidence within 100 days since alloSCT, chronic GVHD incidence after 100 days and 83 
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overall survival (OS). The study sample size was calculated to estimate the 1-year PFS and corresponding 90% one 84 
sided confidence interval. In a retrospective series of 115 patients with relapsed/refractory B-cell NHL, 1-year PFS was 85 
70%, with 20% relapses (5). Assuming no treatment effect on NRM and a 35% relative improvement of relapse rate 86 
(from 20% to 13%), at a significance level of 10% (one-side test) a sample size of 190 assessable patients ensured a 87 
80% probability of detecting a 70% to 77% increase in 1-year PFS. However, due to an expansion of trials 88 
incorporating novel agents and due to an increase of haploidentical donor use the accrual rate decreased in the last two 89 
years and the Data Safety and Monitoring committee suggested to stop enrollment also because a change in PFS was 90 
very unlikely. Therefore, the primary endpoint of improving PFS was not meet. We also analyzed our study, using the 91 
novel composite end point of GRFS  that gives more informations regarding GVHD. 92 
 93 
Response criteria and Statistical analysis 94 
The response to therapy was evaluated at 1, 3, 6 months after alloSCT and every 6 months thereafter and was measured 95 
using the International Workshop NHL criteria, as previously described (17). Acute GVHD was evaluated using the 96 
criteria previously described by Glucksberg et al. (18). Chronic GVHD was diagnosed according to the Seattle criteria 97 
(19). Chronic GVHD was not evaluated by the NIH criteria, considering the study was designed before 2007. The 98 
occurrence of NRM, relapse, and acute and chronic GVHD were estimated in a competing risks setting using 99 
cumulative incidence estimates and the curves were compared by means of  the Gray Test. In the estimation of GVHD, 100 
death without GVHD was evaluated as a competing event. NRM and relapse were competing events each other (20). 101 
We tested also the recent composite end point GRFS (21), introduced in the 2015, which reflects the survival free of 102 
major complications. GRFS events were defined as grade 3-4 acute GVHD or chronic GVHD requiring systemic 103 
immunosuppressive treatment at any time, disease relapse or death from any cause during the first 12 and 36 months 104 
after alloSCT. The OS, PFS, and GRFS curves were estimated using the Kaplan-Meier method and the curves were 105 
compared by means of  the log-rank test. Univariable and multivariable analyses were performed using Fine and Gray 106 
(GVHD, NRM, relapse) or Cox regression models (OS, PFS, GRFS) to assess association between baseline 107 
characteristics and the end-points (22) The statistical association level was evaluated by means of Wald tests. In all the 108 
analysis, age at transplantation was evaluated as continuous variable using 3-knot restricted cubic spline. In the 109 
multivariable analysis for the evaluation of factors influencing acute and chronic GVHD, variables (age, donor type and 110 
donor gender) were chosen based on clinical considerations, and we did not apply any statistical procedure for variable 111 
selection.  Statistical analyses were performed with SASTM (SAS Institute, Cary, NC) and R software (R Development 112 
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Core Team (2012). R: A language and environment for statistical computing. R Foundation for Statistical Computing, 113 
Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org/. Last access: July 7th 2016).  114 
 115 
Results 116 
Patient characteristics 117 
One hundred and twenty-one relapsed/refractory lymphoma patients were enrolled in this multicenter  prospective 118 
phase II trial (refer to Table 1 for baseline characteristics of patients). The median age was 52 years (range, 24-65 119 
years). Diagnoses were de novo or transformed  DLBCL (N=35 of which 2 transformed and 33 de novo), MCL (N=22) 120 
and indolent lymphomas (FL, N=35; CLL/SLL, N=29). Sixty-seven out of 121 (55%) underwent transplantation from a 121 
related sibling (one mismatched siblings in only 2 cases) and fifty-four (45%) received a graft from an unrelated donor 122 
(34 matched, 20 mismatched). Twelve patients had mismatches in class I, the rest in class II, interestingly only 3 123 
patients out of 20 patients (15%) had antigenic mismatches at locus C. It is important to say that most of the patients 124 
had a chemosensitive disease [CR, N=48 (39%); PR, N=61 (51%)] at transplant.  125 
 126 
Cumulative Incidence of Non-relapse Mortality (NRM) and Graft-versus-Host disease (GVHD) 127 
At a median follow-up of 41 months (range, 6-95 months), 24 patients died (20%) of treatment-related causes: acute 128 
GVHD (N=5), chronic GVHD (N=3), infections (N=11), thrombotic microangiopathy (N=1), cardiovascular 129 
complications (N=3), liver failure (N=1). The estimated 1-year and 3-years crude cumulative incidence (CCI) of NRM 130 
was 16% (95%CI, 11%-25%) and 21% (95%CI, 14%-30%), respectively (Figure 1). Non-relapse mortality, by 131 
univariate analysis (Table S1), was not affected by donor type [CCI at 1-year: 14% versus 19% in matched sibling 132 
donors and unrelated donors, respectively (p=0.325)] nor by lymphoma subtype [CCI at 1-year: 16% versus 17% in 133 
indolent and aggressive lymphomas, respectively (p=0.800)].  When we performed a multivariate analysis, NRM did 134 
not appear to be influenced either by age at transplant, or histotype, or by a previously failed autoSCT (Table 2). 135 
However, a higher hazard ratio was estimated for sex mismatch [female donor to male recipient versus other 136 
combinations: HR 2.5 (95%CI, 0.91-6.97), p=0.076], although results remained non-significant. Twenty-six patients 137 
(22%) were diagnosed with acute GVHD grade II-IV (N=16 grade II, N=9 grade III and only one subject grade IV) 138 
with an estimated CCI of 22% (95%CI, 15%-30%). Two patients experienced late onset acute GVHD beyond day 100 139 
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and were excluded from the CCI evaluation. The CCI of acute GVHD was not significantly different in patients 140 
receiving graft from sibling and from unrelated donors (21% versus 22%, respectively).  141 
Ninety-four patients (77%) were evaluable for chronic GVHD whereas the others 27 were not included for early deaths 142 
(N=18), short follow-up (N=7), or an overlapping syndrome of acute and chronic GVHD (N=2). The CCI of chronic 143 
GVHD at 3 years was 44% (95%CI, 34%-56%) with a median time to onset of 353 days. Curves related to Acute and 144 
Chronic GVHD were reported on Figure 1. According to the modified Seattle criteria, the CCI of extensive GVHD was 145 
17% (95%CI, 11%-27%) whereas the limited form was 27% (95%CI, 19%-39%) (Figure  S1). In the univariable Fine 146 
and Gray model, the only factor that was protective against the occurrence of GVHD was the transplant from unrelated 147 
donors when rituximab and ATG were combined together [HR 0.50 (95%CI, 0.25-0.99), p=0.05]. The CCI of chronic 148 
GVHD at 3 years was 54% (95%CI,42%-71%) and 31% (95%CI, 19%-49%) for patients allografted from matched 149 
sibling and unrelated donors, respectively (p=0.04). The analysis of association between the occurrence of acute and 150 
chronic GVHD with different endpoints was performed by including each GVHD type as time-dependent covariate in 151 
univariable Cox Model.  The occurrence of acute GVHD increased significantly the risk of NRM [HR. 3.33, (1.44-7.71, 152 
p=0.005).  Non-relapse mortality, Acute and Chronic GVHD were not affected by donor type (matched sibling, 153 
matched and mismatched unrelated) (curves were reported on Supplemental Material). There were no cases of EBV 154 
lymphoproliferative disorders. 155 
 156 
Relapse  157 
Thirty patients relapsed (25%) and 18 of them died of disease (N=11 aggressive DLBCL, N=7 CLL). The CCI of 158 
relapse was 19% (95%CI, 13%-28%) at 12 months and 27% (95%CI, 19%-37%) at 3 years. In particular, the CCI of 159 
relapse at 3 years was 17% and 34% in indolent and aggressive histotypes, respectively (p=0.011). By multivariate 160 
analysis, a positive bone marrow infiltration at the time of transplant [adjusted HR 3.18, (95%CI, 1.16-8.66), p=0.024] 161 
and aggressive histotypes [adjusted HR , (95%CI, 3.03, (95%CI, 1.14-8.08), p=0.026] were associated to a higher 162 
relapse risk.    163 
 164 
Progression-free survival (PFS), Overall survival (OS) and Graft-versus-host disease-free, relapse-free survival 165 
(GRFS) 166 
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Seventy-nine (65%) patients are currently alive, with a median follow-up for surviving patients of 41 months (range, 6-167 
95 months). The estimated 3-years progression-free and overall survival were 50% and 61%, respectively. (Figure 2). 168 
At 3 years, the PFS and OS were as follows in the different subtypes:  70% (95%CI, 52%-82%) and 76% (95%CI, 59%-169 
86%) in FL, 60%, (95%CI, 40%-75%) and 66% (95%CI, 45%-80%) in CLL/SLL, 40% (95%CI, 23%-57%) and 52% 170 
(95%CI, 32%-68%) in DLBCL, and 52% (95%CI, 28%-71%) and 66% (95%CI, 39%-83%) in MCL. In the two cohorts 171 
(indolent and aggressive) we have evaluated the impact of different prognostic factors on PFS and OS: 1) time from 172 
diagnosis to allogeneic transplantation, 2) previous autologous transplant; 3) disease status at time of allograft (CR 173 
versus others). Neither of these factors influenced significantly PFS or OS. In indolent subtype, patients in CR had a 174 
better PFS although not statistically significant [3 years: 73% (95%CI, 50%-86%) versus 52% (95%CI, 35%-67%), 175 
p=0.099] but the status of disease did not influence OS.  In aggressive subtype, there was again a better survival for 176 
patients allografted in CR [3 years: 75% (95%CI, 49%-88%) versus 43% (95%CI,23%-61%),p=0.091] but was not 177 
statistically significant. 178 
Univariate analysis for all the patients is shown in the Supplementary method (Table S2). The multivariate analysis for 179 
the PFS and OS showed that patients affected by an aggressive histotype had a worst outcome [PFS, HR 3.30 180 
(p=0.003); OS, HR 3.73 (p=0.007)]. Bone marrow infiltration at time of transplant increased the risk of disease relapse 181 
and death [PFS, HR 4.78 (p<0.001); OS, HR 6.00 (p<0.001)]. The occurrence of acute GVHD was associated to shorter 182 
OS [(HR: 2.31 (1.20-4.44, p=0.012)].  183 
For the entire cohort of patients, the 1-year and 3-year GRFS were 40% (95%CI, 32%-50%) and 34% (95%CI, 26%-184 
44%), respectively. The GRFS at 3 years was significantly better in patients with indolent as opposed to aggressive 185 
lymphomas [43% (95%CI, 32%-58%) versus 22% (95%CI, 13%-38%), HR 1.69 (p=0.02)], mainly because of a lower 186 
relapse risk. These figures remained unchanged also at 5 years (data not shown). The 3-year GRFS was 41% and 30% 187 
in patients with complete remission (CR) and partial remission (PR) at the time of transplant, respectively (p=0.075). 188 
There was a trend for a better outcome in CR patients. The 3-year GRFS was 27% and 41% in patients allografted from 189 
matched sibling and unrelated donors, respectively (p=0.096). Distribution of individual components of GRFS is given 190 
in Supplementary Methods (Figure S5 and S6). Main clinical characteristics were not different between patients 191 
receiving sibling or MUD transplants: therefore the difference in GRFS was caused by a lower chronic GVHD requiring 192 
systemic therapy in patients allografted from unrelated donors. In multivariable model the same factors, affecting PFS 193 
and OS, influenced significantly GRFS [histotype, HR 2.02 (p=0.026); bone marrow infiltration, HR 2.70 (p<0.004)] 194 
(Table 3).   195 




In this large multicenter prospective phase II trial, we explored the effect of the inclusion of R in a RIC regimen for B-197 
cell lymphomas. Our findings showed that: i) 3-year NRM was low (21%); ii) PFS was not improved compared to our 198 
previous data without R; iii) extensive chronic GVHD was low despite the high number of patients (45%) allografted 199 
from unrelated donors; iv) because of R inclusion there were non EBV-related post-transplant lymphoproliferative 200 
disorders; v) a lower incidence of chronic GVHD did not translate in a higher relapse rate. 201 
In a previous trial we showed that alloSCT is an effective option for relapsed/refractory lymphomas. We conducted a 202 
clinical trial in 170 patients with different B and T-lymphoma subtypes allografted only from matched sibling donors 203 
with a RIC regimen and we obtained an encouraging NRM (14%), 56% PFS, but the trial was complicated by 14% CCI 204 
of severe acute GVHD (overall 35%) and 25% of chronic extensive form (overall 49%) (5).  Most of literature reports 205 
show that approximately 50% of patients can be progression-free after alloSCT. In order to improve PFS we designed 206 
the present trial including R in the conditioning regimen, however here we show that there was no benefit in terms of 207 
disease control , but there was an advantage in terms of chronic GVHD occurrence. In general when chronic GVHD 208 
decrease there is an increased relapse rate, but interestingly this was not the case with the addition of R. 209 
Despite several studies, conducted over the last decade, showed a significant decrease in NRM following alloSCT with 210 
RIC regimens (5), further progress is needed to improve GVHD prophylaxis since it is a major determinant of morbidity 211 
and mortality. To improve the above reported results (using also unrelated donors),  we performed the present trial that 212 
included a single dose of  R (500 mg/ms) administered during the conditioning. The rationale for a single pre-transplant 213 
R administration relies on the assumption that circulating CD20+ B cells of the recipient had already been depleted by 214 
R-supplemented salvage chemo-immunotherapy whereas pre-transplant  R will probably work largely by depleting the 215 
donor’s alloreactive B cells (and thus preventing also EBV reactivation) in the first 3 months after transplantation. In 216 
the current study, we had an incidence of acute GVHD (21% and 22% in transplant from related and unrelated donors, 217 
respectively) that was lower than in our previous study without R (35%) that included only patients allografted from 218 
HLA matched siblings and the same conditioning regimen and GVHD prophylaxis (5). The 3-year CCI of chronic 219 
GVHD was 31% versus 54% in patients allografted from unrelated and related donors, respectively. This finding is 220 
clinically relevant and could be related to the high dose ATG used or to a potential synergistic effect of R and ATG. 221 
This result substantially contributes in generating a 41% GRFS in patients allografted from unrelated donors. The dose 222 
of ATG in our trial was not associated to unacceptable risk of infection and derived  from a previous italian trial (23) 223 
that evaluated two different GVHD prophylaxis strategies [ATG at 7.5 mg/kg versus Alemtuzmab] in patients 224 
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allografted from unrelated donors [8/8 or 7/8 (a allele mismatched was allowed)]. For all the patients the cumulative 225 
incidence of acute and chronic GVHD were 44% and 25%, respectively.  226 
The impact of R on B-cell depletion has been previously evaluated in different trials with somehow conflicting results. 227 
First, the dose, the timing and the duration of antibody administration was variable. Second, these studies were not well 228 
comparable each other not only for the type of patients enrolled, but also for differences in the conditioning regimens as 229 
well as in the type and dose of the drugs used for GVHD prophylaxis (e.g., anti-thymocyte globulin) (14-15). Khouri et 230 
al. (14) were the first to explore the administration of high-dose R (before and after transplant) and reported results with 231 
a mature follow-up. They showed an impressive low incidence (10%) of grade III-IV acute GVHD and of extensive 232 
chronic GVHD (36%), which appeared to be not only related to patient selection (mainly matched sibling donors) but 233 
also to antibody administration. In that study also R naive patients were included. In a more recent paper (24),  the same 234 
authors explored a new reduced-conditioning regimen (Bendamustine, Fludarabine and Rituximab), but they introduced 235 
also a low dose ATG for recipients of unrelated grafts. The 2-year cumulative incidence of chronic GVHD was 26% in 236 
patients allografted from unrelated donors that is comparable with our results. Recently, Laport et al. (25) performed a 237 
prospective trial using the FCR regimen in a population of 65 patients allografted from matched sibling and unrelated 238 
donors. The authors did not use antithymocyte globulin and the cumulative incidence of chronic GVHD for unrelated 239 
recipients was 66%. Despite that, the study was interesting because they found  an association between higher R serum 240 
concentration and better outcome, and lower serum concentration and severe acute GVHD. Cutler et al. (15) explored 241 
different R infusions after day 100 demonstrating a 30% incidence of chronic GVHD requiring systemic corticosteroids 242 
(lower than 48% observed in the historical control) in patients transplanted from related and unrelated donors.  243 
In contrast to the above studies, Glass et al. (16) evaluated the effect of post-transplant R in a randomized trial and did 244 
not observe any significant effect on either acute or chronic GVHD. However, the major limitation of this prospective 245 
trial was the use of ATG in a minority of patients allografted from unrelated donors and the discontinuation of R in a 246 
substantial number of patients (61%) allocated to the R group.  247 
Recent randomized trials, performed mainly in myeloid malignancies, strongly supported the use of ATG as GVHD 248 
prophylaxis in patients receiving alloSCT not only from unrelated donors (26), but also from HLA-identical siblings 249 
(27). The benefit was mainly related to a reduction of the severe forms of chronic GVHD.   250 
Epstain Barr virus  reactivation is common (33%) after allogeneic transplantation from unrelated donors when the 251 
GVHD prophylaxis included  anti-thymocyte globulin as recently reported also in the paper of Walker et al. (26). High 252 
levels of EBV DNAemia increase the risk of post-transplant lymphoproliferative disorders (PTLD). The use of 253 
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prophylactic Rituximab (200 mg on day +5) has been explored in a retrospective study (28) in recipients of transplant 254 
from alternative donor (the GVHD prophylaxis included rabbit anti-thymocyte globulin at dose of 6-10 mg/kg) and was 255 
associated to a lower rate of EBV DNAemia and  to the absence of cases of PTLD as compared to control group.  In our 256 
study the administration of Rituximab  prevented efficiently the Epstain Barr virus  reactivation and the PTLD. 257 
Our trial expands the knowledge about the role of transplant in relapsed/refractory aggressive lymphomas. In fact, we 258 
demonstrated that at 3 years 54% of patients failing an autologous stem cell transplant and 43% of patients not in CR 259 
are alive. These data compare favourably with the results reported by Glass et al.(16) in patients with refractory disease 260 
at time of alloSCT (estimated 3 years OS of 38%) and with those described by Fenske T. et al. (29) in retrospective 261 
study enrolling patients progressing after autologous stem cell transplantation (estimated 3 years OS of 37%).  262 
In the last years, a number of novel agents for lymphomas became available. Major advances occurred in 263 
relapsed/refractory CLL, MCL and FL using the Bruton tyrosine kinase inhibitors (ibrutinib), the inhibitor of BCL-2 264 
venetoclax and phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor idelalisib (30-33). All these studies have intrinsic 265 
limitations mainly due to the very short follow-up and also the long-term efficacy and safety is lacking. The question of 266 
which strategy (RIC alloSCT or new drugs) is better for the treatment of transplant eligible patients is now open and 267 
appropriately designed prospective clinical trials will be required to challenge the 34% of patients that are alive and free 268 
of any complication after alloSCT.  269 
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Figure 1. A) Crude cumulative Incidence (CCI) of Non-Relapse Mortality. At 3 years the CCI of NRM was 21% 
(95%CI, 14%-29%); B) CCI of acute GVHD grade II-IV at 100 days: 21% (95%CI,15%-30%); C) CCI of limited and 
extensive chronic GVHD: 27% (95%CI, 19-38%) and 17% (95%CI, 11%-27%), respectively. 
 
Figure 2. Kaplan-Meier estimates of Progression-free Survival and Overall Survival. A) Progression-Free Survival at 5 
years was 49% (95%CI, 40%-61%); B) The Overall Survival at 5 years was 61% (95%CI, 51%-71%).  
 
Figure 3. Adjusted Kaplan-Meier estimates of Graft-versus-Host Disease-free and  Relapse-free survival (GRFS) at 3 
years  after allogeneic stem cell transplantation. A) GRFS for all the patients: 34% (95%CI, 26%-44%); B)  GRFS 
according to donor type: 27% and 41% in patients allografted from matched sibling donors and unrelated donors, 
respectively (p=0.09).  
 
Figure 4. Adjusted Kaplan-Meier estimates of Graft-versus-Host Disease-free and  relapse-free survival (GRFS) at 3 
years  after allogeneic stem cell transplantation. A) GRFS upon hystotype: 43% indolent (95%CI, 32%-58%) versus 
22% aggressive lymphomas (95%CI, 13%-38%), (p=0.02); B) GRFS upon pre-transplant disease status: 41% (95%CI, 
28%-59%) and 30% (95%CI, 20%-44%) for patients in complete and partial remission, respectively (p=0.185). 
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Table  1. Patients characteristics  
  
  N 
(121) 
% 
        
Age at AlloSCT, median (range) 52 (23-65)   
Gender                                 
  
Male 80 66% 
  
Female 41 34% 
Karnofsky performance  status     
  
≤80 18 15% 
  
>80 103 85% 
Diagnosis*     
  
FL 35 28% 
  
CLL/S CLL 29 24% 
  
DLBCL 35 28% 
  
MCL 22 18% 
Bone Marrow involvement     
  
Yes 30 25% 
  






Extranodal involvement     
  
Yes 26 21% 
  
No 78 64% 
  
Missing 17 14% 
PriorAutoSCT 
ASCT   
 
Yes 74 61% 
 
No 47 39% 
Disease Status at Transplant     
  
CR 48 40% 
  
PR 64 53% 
  
PD/SD 9 7% 
Donor Type     
  
Matched/Mismatched Related ** 67 55% 
  
Matched Unrelated  34 28% 
  
Mismatched Unrelated   20 17% 
 
Sex mismatched 
                            
  
 






















    




















Year of Allotransplant     
  
2007-2011 65 54% 
  
2012-2015 56 46% 
Abbreviations: AlloSCT, allogeneic stem cell transplantation; FCL, follicular cell lymphomas; CLL/SLL, chronic 
lymphocytic leukemia; SLL, small lymphocytic lymphomas; DLBCL, diffuse large B cell lymphomas; MCL; mantle 
cell lymphomas; CR, complete remission; PR, partial remission; PD, progressive diasese; SD, stable disease; autoSCT: 
autologous stem cell transplantation; PBSC, peripheral blood stem cells; BM, bone marrow.   
*diagnosis were well balanced:  
34 and 30 indolent lymphomas patients were transplanted from matched /mismatched related sibling, respectively;  
33 and 20 patients with aggressive lymphomas were allografted from matched/mismatched unrelated donors;  
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Table 2. Multivariable analysis on Non-relapse mortality and Relapse  271 




        
      HR (95% CI) p-value   HR (95% CI) p-value 
                
Age at AlloSCT             
  46 Vs 57*   1.45 (0.73-2.86) 0.55   --- --- 
                
Histotype subgroup             
  Aggressive vs Indolent   1.07 (0.44-2.60) 0.891   3.03 (1.14-8.08)  0.026 
                
Bone Marrow involvement             
  Yes Vs No   --- ---   3.18 (1.16-8.66) 0.024 
                
Extranodal involvement             
  Yes Vs No   --- ---   0.95 (0.28-3.18) 0.930 
                
Prior AutoSCT             
  Yes vs No             1.82 (0.66-5.06) 0.250   1.11 (0.35-3.47)  0.860 
                
Donor Type             
  Unrelated Vs Related   1.75 (0.75-4.08) 0.197   0.80 (0.31-2.05) 0.640 
                
Sex mismatched             
  
Female donor-Male recipient Vs Other 
combinations 
  
2.52 (0.91-6.97) 0.076   0.12 (0.01-1.15) 0.067 
Abbreviations: NRM, non-relapse mortality; HR: sub-distribution hazard ratio from Fine and Gray model; 95% CI, 
95% confidence interval of HR; p value, Wald test p value; AlloSCT, allogeneic stem cell transplantation; * Age was 
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Table 3. Multivariable analysis on PFS, OS, GRFS 






          
      HR (95% CI) p-value   HR (95% CI) p-value   HR (95% CI) p-value 
                      
Age at AlloSCT                   
  46 Vs 57*   1.63 (0.93-2.85) 0.234   1.70 (0.91-3.18) 0.22   1.62 (1.02-2.55) 0.113 
                      
Histotype subgroup                   
  Aggressive vs Indolent   3.30 (1.49-7.30)  0.003   3.73 (1.42-9.78) 0.007   2.02 (1.09-3.77) 0.026 
                      
Prior autoSCT                   
  
Yes vs No   
1.34 (0.60-3.02) 0.476   1.20 (0.48-3.00) 0.696   1.55 (0.78-3.05) 0.208 
                      
Bone Marrow involvement                   
  Yes Vs No   4.79 (2.12-10.82) <0.001   6.00 (2.10-14.15) <0.001   2.70 (1.37-5.32) 0.004 
                      
Extranodal involvement                   
  Yes Vs No   0.87 (0.40-1.90) 0.728   1.07 (0.45-2.53) 0.884   1.54 (0.82-2.89) 0.177 
                      
Donor Type                   
  Unrelated Vs Related   1.28 (0.59-2.76) 0.529   1.35 (0.56-3.3.30) 0.506   0.79 (0.41-1.51) 0.472 
                      
Sex mismatched                   
  
Female donor-Male recipient Vs 
Other combinations 
  
1.21 (0.48-3.04) 0.690   1.50 (0.53-4.26) 0.449   1.41 (0.68-2.91) 0.352 
Abbreviations: PFS, progression-free survival; OS, overall survival; GRFS, graft-versus-host disease-free/relapse-free 
survival; HR: hazard ratio from Cox model; 95% CI, 95% confidence interval of HR; p value, Wald test p value; 
AlloSCT, allogeneic stem cell transplantation; autoSCT, autologous stem cell transplantation;  * Age was evaluated as 
continuous variable. The two values are, respectively, the 3rd and 1st quartiles of the variable distribution. 
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